Abstract
The aim of the present study was to investigate the renal effects of long-term treatment with the calcium channel blocker nifedipine in normotensive type 1 diabetic patients with microalbuminuria. In a randomized, double-blind trial, 15 type 1 diabetic patients were treated with either nifedipine (n=8; dosage 30 mg/day) or placebo (n=7) for 12 months. At baseline and after 6 and 12 months of therapy, the albumin excretion rate (UAER, radioimmunoassay), glomerular filtration rate (GFR, chromium 51 ethylenediamine tetra-acetic acid clearance) and renal plasma flow (RPF, iodine 125 hippuran clearance) were determined. Nifedipine treatment caused a significant reduction of UAER after 6 and 12 months (median, Q1/Q3 in mg/24 h): baseline 84 (65/163); 6 months 35 (23/90),P<0.02; 12 months 39 (15/79),P<0.05. GFR was significantly decreased by nifedipine treatment (baseline 157±15, 6 months 122±8, 12 months 111±47 ml/min;P<0.05, mean ± SEM), whereas RPF remained constant. Nifedipine treatment did not influence systolic (baseline 121±7, 12 months 124±2 mmHg, mean ± SEM) or diastolic (baseline 72±2, 12 months 74±3 mmHg) arterial blood pressure. With placebo treatment no significant alterations of UAER, GFR, RPF and arterial blood pressure were observed. Metabolic control was constant throughout the whole study period. Thus, 1 year's treatment with nifedipine reduces the UAER and GFR in normotensive type 1 diabetic patients without influencing the systemic arterial blood pressure. The data, however, do not present a recommendation for the general use of nifedipine in these patients as the exact intrarenal mechanism of calcium channel blockers in humans remains to be established.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mogensen CE, Christensen CK, Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89–93, 1984
Viberti GC, Jarrett RJ, Mahmud U, Hill RD, Argryropoulos A, Keen H, Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1:1430–1432, 1982
Mogensen CE, Management of diabetic renal involvement and disease. Lancet 1:867–870, 1988
Parving HH, Smidt UM, Andersen AR, Svendsen PA, Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175–1178, 1983
Parving HH, Hommel E, Prognosis in diabetic nephropathy. Br Med J 299:230–233, 1989
Zatz R, Dunn BR, Meyer TW, Anderson A, Rennke HG, Brenner BM, Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925–1930, 1986
Marre M, Leblanc HS, Guyenne TT, Menard J, Passa P, Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J 294:1448–1452, 1987
Mathiesen ER, Hommel E, Giese J, Parving HH, Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br Med J 303:81–87, 1991
Rudberg S, Aperia A, Freyschuss U, Persson B, Enalapril reduces microalbuminuria in young normotensive type 1 (insulin dependent) diabetic patients irrespective of its hypertensive effect. Diabetologia 33:470–476, 1990
Wiegmann TH, Gish Herron K, Chondo AM, L McDougall M, Moore WV, Effect of angiotensin-converting enzyme inhibition of renal function and albuminuria in normotensive type 1 diabetic patients. Diabetes 41:62–67, 1992
Christensen CK, Mogensen CE, Effect of antihypertensive treatment progression of incipient diabetic nephropathy. Hypertension 11:109–113, 1985
Mimram A, Insua A, Ribstein J, Bringer J, Monnier L, Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care 11:850–853, 1988
Baba T, Murabayashi S, Takebe K, Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin dependent) diabetic patients with microalbuminuria: a randomized control trial. Diabetologia 32:40–44, 1989
Brochner-Mortensen J, A simple method for determination of glomerular filtration rate. Scand J Clin Lab Invest 30:35–45, 1972
Brochner-Mortensen J, Rodbro P, Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36:35–45, 1976
Ram MD, Evans K, Chisholm GD, Measurements of effective renal plasma-flow by the clearance of125I-hippuran. Lancet 2:645–646, 1967
Pedersen MM, Mogensen CE, Jorgensen FS et al, Renal effects from limitation of high dietary protein in normoalbuminuric insulin-dependent diabetic patients. Kidney Int (Suppl) 27:115–121, 1989
Cohen DL, Dodds R, Viberti GC, Effect of protein restriction in insulin dependent diabetics at risk of nephropathy. Br Med J 294:795–798, 1987
Feldt-Rasmussen B, Mathiesen E, Deckert T, Effect of two years of strict metabolic control on the progression of incipient nephropathy in insulin-dependent diabetes. Lancet 2:1300–1304, 1986
Mathiesen ER, Oxenboll B, Johansen K, Svendsen PA, Deckert T, Incipient nephropathy in type 1 (insulin dependent) diabetes. Diabetologia 26:406–410, 1984
Chan JCN, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R, Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. Br Med J 305:981–985, 1992
Bretzel RG, Bollen CC, Maeser E, Federlin KF, Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 21 (Suppl 3):53–64, 1993
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M, Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577–581, 1993
Drummond K, Levy-Marchal C, Laborde K et al, Enalapril does not alter renal function in normotensive, normo-albuminuric, hyperfiltering type 1 (insulin-dependent) diabetic children. Diabetologia 32:255–260, 1989
Pedersen MM, Schmitz A, Pedersen EB et al, Acute and long term renal effects of angiotensin converting enzyme-inhibition in normotensive, normoalbuminuric insulin-dependent diabetic patients. Diabetic Med 5:562–569, 1988
Melbourne Diabetic Nephropathy Study Group, Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 302:210–216, 1991
Stornello M, Valvo EV, Scarpellato L, Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type 2 diabetic patients with nephropathy. J Cardiovasc Pharmacol 14:851–855, 1989
Bakris GL, Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 112:707–708, 1990
Loutzenhiser R, Epstein M, Renal microvascular actions of calcium antagonists. J Am Soc Nephrol 1:3–12, 1990
Anderson S, Rencke HG, Zoyas MA, Brenner BM, Chronic calcium channel blockade fails to lower glomerular pressure and albuminuria in diabetic rats. Clin Res 39:247A, 1991
Mogensen CE, Christensen CK, Vittinghus E, The stages of diabetic renal disease with emphasis on the stage of incipient nephropathy. Diabetes 32 (Suppl 2):64–78, 1983
Hostetter TH, Rennke HG, Brenner BM, The case of intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72:375–380, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schnack, C., Capek, M., Banyai, M. et al. Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria. Acta Diabetol 31, 14–18 (1994). https://doi.org/10.1007/BF00580754
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00580754